Drug Approval | August 12, 2021
Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness
A treatment to prevent extreme symptoms and cut hospitalisation
A treatment to prevent extreme symptoms and cut hospitalisation
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The company is eligible for 12 months exclusivity from launch
The American Association for Clinical Chemistry (AACC); the American Society for Clinical Pathology (ASCP); the American Society of Hematology (ASH); and the International Myeloma Working Group (IMWG), collaborate to develop the guideline
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection
The collaboration will support Canada with direct access to rapid pandemic response capabilities
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The aim is to create new genomics solutions that could combat cancer and advance market access
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
